CG Oncology, Inc.(CGON)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,594 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CGON
Events flagged as statistical outliers against CGON's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-09
CGON quality score dropped 13 points (28→15) on a new filing
View source filing →
CGON Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for CG Oncology, Inc. (CGON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CGON at 27.0/100 on a 32-signal composite quality model, placing it at rank #2,594 of 2,961 stocks — the bottom half of the AI-ranked universe. CGON scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (1.0) and profitability (1.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CG Oncology, Inc. reports quarterly revenue of $1.2M, net income of $-79.1M, free cash flow of $-46.9M. Top institutional holders of CGON by reported 13-F value include RTW INVESTMENTS, T. Rowe Price Investment Management, Decheng Capital, based on the most recent SEC filings. CGON trades on the Nasdaq exchange and files with the SEC under CIK 1991792. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CG Oncology, Inc. directly from SEC EDGAR. CG Oncology, Inc.'s 13F Pro composite quality score has ranged between 15 and 30 since 2026, currently 27.0 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.2M
Net Income
Q2 2026
$-79.1M
Free Cash Flow
Q2 2026
$-46.9M
ROIC
Q2 2026
-33.5%
D/E Ratio
Q2 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+254.7% YoYNet Income
-82.9% YoYOperating Income
-66.4% YoYEPS (Diluted)
-47.5% YoYTotal Assets
+4.9% YoYTotal Debt
Op. Cash Flow
-68.1% YoYFree Cash Flow
-67.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $4.0M +254.7% | $1.1M +458.3% | $204.0K | — |
| Net Income | $-161.0M -82.9% | $-88.0M -81.1% | $-48.6M | — |
| Operating Income | $-190.8M -66.4% | $-114.7M -106.8% | $-55.4M | — |
| EPS (Diluted) | $-2.08 -47.5% | $-1.41 +91.0% | $-15.65 | — |
| Total Assets | $791.6M +4.9% | $754.8M +278.7% | $199.3M | — |
| Total Debt | $3.0M | $0.00 | — | — |
| Operating Cash Flow | $-132.3M -68.1% | $-78.7M -72.3% | $-45.7M | — |
| Free Cash Flow | $-132.5M -67.8% | $-78.9M | — | — |
Get alerted when CGON's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CG Oncology, Inc. including:
Top Institutional Holders of CGON
RTW INVESTMENTS, LP
$605.0M8,514,590 shT. Rowe Price Investment Management, Inc.
$470.1M6,616,899 shDecheng Capital LLC
$452.7M6,371,669 shBlackRock, Inc.
$444.5M6,256,288 shWELLINGTON MANAGEMENT GROUP LLP
$378.3M5,324,751 shFMR LLC
$295.7M4,161,493 shPRICE T ROWE ASSOCIATES INC /MD/
$270.3M3,805,010 shTCG Crossover Management, LLC
$260.8M3,670,206 shVANGUARD PORTFOLIO MANAGEMENT LLC
$246.2M3,465,197 shSTATE STREET CORP
$244.2M3,437,590 sh
| Fund | Value | Shares |
|---|---|---|
| RTW INVESTMENTS, LP | $605.0M | 8,514,590 |
| T. Rowe Price Investment Management, Inc. | $470.1M | 6,616,899 |
| Decheng Capital LLC | $452.7M | 6,371,669 |
| BlackRock, Inc. | $444.5M | 6,256,288 |
| WELLINGTON MANAGEMENT GROUP LLP | $378.3M | 5,324,751 |
| FMR LLC | $295.7M | 4,161,493 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $270.3M | 3,805,010 |
| TCG Crossover Management, LLC | $260.8M | 3,670,206 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $246.2M | 3,465,197 |
| STATE STREET CORP | $244.2M | 3,437,590 |
Companies Similar to CGON
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Tango Therapeutics, Inc.
AGIOS PHARMACEUTICALS, INC.
Kymera Therapeutics, Inc.
Janux Therapeutics, Inc.
Verastem, Inc.
CYTOKINETICS INC
RHYTHM PHARMACEUTICALS, INC.
Cue Biopharma, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CGON on your watchlist
Track score changes the day CG Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CGON a good stock to buy?
13F Pro's AI-powered analysis of CG Oncology, Inc. (CGON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CGON are available on the CGON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CGON is classified as a mid company.
Which hedge funds own CGON?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CGON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CG Oncology, Inc.'s investment landscape.